“It will be first care at home for early stages”

by time news

“It is the first time that a drug given orally works in anti-Covid therapy and this is an extraordinary fact. I am very proud, because in our center in Genoa the only Italian patient was enrolled in the molnupiravir study. several competing centers and we were the only one to find it, and thanks also to the patient “. Matteo Bassetti, director of the Infectious Diseases Clinic of the San Martino Polyclinic in Genoa, said this to time.news Salute, commenting on the data on the experimental oral antiviral molnupiravir which, according to the companies Msd and Ridgeback Biotherapeutics, shows to reduce the risk of hospitalization and death in patients with mild or moderate Covid. The companies intend to apply for Emergency Use Authorization (Eua) in the United States as soon as possible.

Read also

“The company has decided to interrupt the study for manifest superiority. This antiviral – continues Bassetti – can really become the home treatment in the early stages of Covid, and when it is approved we will have a series of extraordinary treatments for Covid and only 18 months. from the first case of coronavirus. This means that, from the point of view of research, we have made an extraordinary effort and Italy is first in the EU and fourth in the world for scientific contributions on Covid “.

“Antiviral is a synthetic nucleoside derivative that has the ability to inhibit replication by copying wrong viruses – explains Bassetti – In this way it gives wrong information to the virus that it can no longer be dangerous”.

READ Also:  "Right tear Government on Cts"

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.